High expression of fibronectin 1 indicates poor prognosis in gastric cancer.

Fibronectin 1 () is involved in the occurrence and development of various tumors and is upregulated in multiple cancer types. has been demonstrated to promote cell proliferation and migration in gastric cancer cell lines. However, the relationship between the expression of and clinicopathological factors and prognosis is not clear in gastric cancer (GC). The aim of the present study was to investigate the association between expression and clinicopathology and prognosis of gastric cancer. In this study, 17 publicly available GC cohorts (n=2,376) with gene expression data from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and Oncomine databases were tested. In addition, protein expression was validated by immunohistochemistry in a separate cohort (n=190). The meta-analysis results demonstrated an increase in expression at the protein and mRNA level in GC tissues, and the gene was highly expressed at the mRNA level in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. In addition, the expression of epithelial at the protein level was positively correlated with tumor size. expression at the protein and mRNA level was a predictor of poor prognosis following radical resection of GC. In conclusion, the expression of in GC tissues is upregulated compared with adjacent normal tissues, and it is a potential biomarker of poor prognosis in patients with GC.